



**HAL**  
open science

## Short and Mid Term Outcomes of Cryopreserved Abdominal Aortic Allografts Used as a Substitute for Infected Prosthetic Grafts in 200 Patients

Thibault Couture, Julien Gaudric, Sophie Tezenas Du Montcel, Jérémie Jayet, Dorian Verscheure, Jean Michel Davaine, Mohamed Jarraya, Laurent Chiche, Fabien Koskas

► **To cite this version:**

Thibault Couture, Julien Gaudric, Sophie Tezenas Du Montcel, Jérémie Jayet, Dorian Verscheure, et al.. Short and Mid Term Outcomes of Cryopreserved Abdominal Aortic Allografts Used as a Substitute for Infected Prosthetic Grafts in 200 Patients. *European Journal of Vascular and Endovascular Surgery*, 2021, 62 (1), pp.89-97. 10.1016/j.ejvs.2021.02.036 . hal-03854456

**HAL Id: hal-03854456**

**<https://inria.hal.science/hal-03854456>**

Submitted on 15 Nov 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Short- and mid-term outcomes of cryopreserved**  
2 **abdominal aortic allografts used as a substitute for**  
3 **infected prosthetic grafts in 200 patients**

4  
5 **Short title: Short- and mid-term outcomes of aortic allografts**

6 Thibault Couture<sup>a\*</sup>, Julien Gaudric<sup>a\*</sup>, Sophie Tezenas Du Montcel<sup>b</sup>, Jérémie Jayet<sup>a</sup>, Dorian  
7 Versheure<sup>a</sup>, Jean Michel Davaine<sup>a</sup>, Mohamed Jarraya<sup>c</sup>, Laurent Chiche<sup>a</sup>, Fabien Koskas<sup>a</sup>

8  
9 From the <sup>a</sup>Sorbonne Université, Department of Vascular Surgery, Pitié-Salpêtrière Hospital,  
10 Assistance Publique Hôpitaux de Paris, France, <sup>b</sup> Biostatistics Department, Sorbonne  
11 Université, Pitié-Salpêtrière Hospital, UMR\_S1136 ; INSERM UMR\_S1136, Institut Pierre  
12 Louis d'Epidémiologie et de Santé Publique, Paris, France and <sup>c</sup>Université de Paris, Human  
13 Tissue Bank, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, France.

14 \*First co-authors

15 **Corresponding author:** Julien Gaudric, MD PhD, Sorbonne Université, Department of  
16 Vascular Surgery, Pitié-Salpêtrière Hospital, 47-83, bd de l'Hôpital, 75013 Paris, Assistance  
17 Publique-Hôpitaux de Paris, France.

18 E-mail: [julien.gaudric@aphp.fr](mailto:julien.gaudric@aphp.fr)

19 Phone Number: +33663739002

20  
21 Word count: 4319

22

23 **What this paper adds:**

24 This large and homogeneous series of patients allowed quantifying the complication rate of  
25 surgery for abdominal aortic graft infection and the rate of allograft-related complications.

26 Despite acceptable results of allografts used as a substitute for infected aortic prostheses, early  
27 ruptures were observed, due to allograft to reinfection. Anastomotic prosthetic graft

28 pseudoaneurysm upon presentation, regardless of the microorganism involved, was identified  
29 as a predictive factor for allograft rupture. Moreover, a bacteriological confirmation of

30 infection before initiation antibiotics and a rigorous imaging follow-up are recommended.

31

32

33

34

35 **Introduction**

36 The incidence of aortic graft infections (AGI) is low (0.5-6%)<sup>1-3</sup> but is associated with high  
37 morbidity and mortality rates of 10-50%<sup>3-7</sup>. Standard treatment remains controversial ranging  
38 from radical surgery with complete excision of the graft and infected tissues and iterative  
39 vascular repair, to conservative strategies. Some substitutes with infection-resistant properties  
40 are available, including femoral veins, antibiotic- or silver-coated grafts. However, the  
41 substitute showing the best resistance to infection and the best long-term results remains a  
42 matter of debate.

43 Radical surgery using cryopreserved arterial allografts (CAAs) for the iterative repair is our  
44 preferred strategy since the 1980s because several experimental and clinical studies have  
45 shown the resistance of CAAs to colonization by most microorganisms involved in vascular  
46 infections<sup>8-11</sup>. Moreover, CAA is considered a safe<sup>11</sup> and even mechanically ideal material for  
47 arterial repair, at least in the short term, with good outcomes<sup>12</sup>. However, the benefit of such a  
48 strategy remains to be demonstrated in the long term and in large series. Despite the recent  
49 recommendations provided by the European Society of Vascular and Endovascular Surgery<sup>13</sup>,  
50 there is a lack of evidence due to the heterogeneity and small sample sizes of the published  
51 series.

52 This study provided a large database from which solid conclusions could be drawn. Its aim  
53 was to investigate the early and late outcomes of patients with arterial graft infection treated  
54 with complete excision of the infected graft and iterative arterial repair using a CAA starting  
55 from the infrarenal aorta.

56

57 **Patients and methods.**

58

59 **Patients**

60 All consecutive patients treated with CAA for infrarenal aortic repair in prosthetic arterial  
61 infections in our vascular department between January 1997 and December 2013 with a  
62 follow-up until January 2016 were included in a monocentric study. Data were recorded in a  
63 prospectively maintained database and were analyzed retrospectively<sup>14</sup>.

64 Demographics, cardiovascular risk factors, comorbidities and techniques including the CAA  
65 features were recorded.

66 When a diagnosis of graft infection was suspected a Computed Tomography (CT)-scan was  
67 systematically performed to identify a periprosthetic abscess, graft-enteric fistula or  
68 pseudoaneurysm (PA).

69

#### 70 **Bacteriological diagnosis**

71 The microorganisms responsible for infection were identified in bacteriological samples  
72 collected preoperatively by drainage or CT-guided puncture of perigraft pus drainage or in  
73 blood cultures or were directly collected intraoperatively. The analyzed intraoperative  
74 samples included intraprosthetic and PA thrombus, perigraft collection or the graft itself. Our  
75 institutional algorithm recommended to systematically perform bacteriological samples before  
76 initiating antibacterial treatment.

77 The diagnosis of AGI was ascertained using the MAGIC classification<sup>13</sup> if one major criterion  
78 or at least two minor clinical, radiological or biological criteria were present. Infection was  
79 defined as early if it occurred after <4 months and late if it occurred after >4 months<sup>13</sup>.

80 Then, broad-spectrum antibiotics were initiated before secondary targeted antibiotics after  
81 identification of the microorganism by infectious disease specialists.

82 All survivors underwent CT and/or duplex ultrasound examinations before discharge and  
83 were followed with a clinical examination and a new imaging at one and six months and  
84 yearly thereafter.

85 **Cryopreservation protocol.**

86 All CAAs were provided by the tissue bank of our institution (Banque de Tissus de  
87 l'Assistance Publique Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France). Allografts were  
88 obtained from brain-dead multiorgan donors and transported at a temperature between +3 and  
89 +10°C to the bank in 500 mL of gelatin (Plasmion) solution containing antibiotics (160 mg of  
90 gentamicin, 250 mg of vancomycin, 300 mg of Clindamycin or Lincomycin). After 36 hours  
91 in this solution, they were placed in a cryopreservation solution composed of 50 mL of  
92 dimethyl sulfoxide (DMSO) and 350 mL of tissue preservation fluid (Solution de  
93 Conservation des Organes et Tissus, SCOT 30, Macopharma, Mouvaux, France). Allografts  
94 were then frozen in a controlled-rate nitrogen vapor freezing chamber at a rate ranging  
95 between -1°C and -2°C/minute up to -40°C and of -5°C/minute from -40°C to -150°C. CAAs  
96 were then stored in a nitrogen vapor container (-150°C) until their use.

97

98 **Surgical technique.**

99 Exhaustive excision of all synthetic material whether or not macroscopically infected, was  
100 performed in all cases. Aggressive debridement of the surrounding periprosthetic infected  
101 tissues was performed to obtain a macroscopically normal surgical field. Arterial repair was  
102 then performed using one or more CAAs. The allograft was systematically separated from the  
103 bowels using a retroperitoneal tissue or bovine pericardial patch (Edwards Lifesciences,  
104 Irvine, CA, USA) or by omentoplasty.

105 In all cases with graft-to-enteric fistula, the digestive part of the procedure was performed by  
106 a gastrointestinal surgeon as previously described<sup>15</sup>. The digestive procedure ranged from a  
107 simple suture of the bowel to resection and anastomosis with the third portion of the  
108 duodenum depending on the tissue loss and fistula location.

109 Peroperative surgical data and CAA features were collected (intervention duration, blood loss,

110 number of allografts used, clamping level, need for vasoactive drugs, surgical procedure).

111

### 112 **Postoperative parameters**

113 Postoperative (at 30 day and in-hospital) mortality and systemic morbidities were recorded.

114 In-hospital complications requiring revision surgery were also collected. During the follow-up,

115 the need for allograft-related revision surgery, aneurysmal degeneration and thrombosis,

116 reinfection, survival and limb salvage were recorded. Ruptures were considered a reinfection

117 if no mechanical factors were found after reviewing the operative reports.

118

### 119 **Outcomes**

120 The primary outcome was the allograft-related revision surgery rate. Secondary outcomes

121 were the rates of 30-day mortality, survival, primary patency, limb salvage and infection

122 recurrence.

123

### 124 **Statistical analysis.**

125 Data are presented as a frequency (percentage) for qualitative variables and a mean  $\pm$  standard

126 deviation for quantitative variables. Statistical analysis was performed using SAS software

127 (version 9.4, SAS Institute, Cary, NC).

128 The analysis of the long-term mortality, primary patency, and graft-related complication-free

129 survival was performed using the Kaplan-Meier method. Potential risk factors for early

130 mortality were identified using univariate and multivariate logistic regression analysis.

131 Univariate factors associated with a p-value  $<.20$  were included in the multivariate analysis

132 using a stepwise selection. Odds ratios (OR) with their respective 95% confidence intervals

133 (CI) were computed. Risk factors for short-term septic complications and long-term

134 complications were analyzed using a Cox model according to the method of Fine and Gray.

135 For the long-term risk factors, patients who died, were lost to follow-up or underwent  
136 allograft explantation before 6 months were excluded from the analysis. For both analyses,  
137 hazard ratios (HR) with their 95% CI were computed. A p-value <.050 was considered  
138 significant. The conduct of this study was approved by our institutional review board under  
139 the number 20190906192459.

140

## 141 **Results**

### 142 Patient demographics and clinical presentation

143 Over the study period, 200 patients with a mean age of  $64.2 \pm 9.4$  years were included (**Table**  
144 **1**). The indication for primary surgery was a non-infected aneurysmal or occlusive disease in  
145 65 and 135 cases, respectively. The mean time between initial surgery and the diagnosis of  
146 infection was  $58 \pm 65$  months. In 51 cases (25.5%), infection occurred less than 4 months  
147 after initial surgery.

148 The diagnosis of infection was made based on major clinical or radiological criteria in 167  
149 cases (83.5%) (prosthetic-digestive fistula, periprosthetic abscess, cutaneous fistula). In case  
150 of minor criteria (PA or graft thrombosis), the diagnosis was confirmed by collecting  
151 microorganisms from the explanted grafts or intra-operative specimen or inflammatory  
152 syndrome according to the MAGIC classification<sup>13</sup>. Among the patients with major criteria,  
153 14 also had a PA.

### 154 Bacteriology

155 Microbiological findings are reported in **Table 2**.

156 All patients received antibiotics postoperatively and 172 (86%) preoperatively. The mean  
157 duration of antibiotherapy was  $57.3 \pm 91$  days.

158 The bacteriological samples were negative in 35 patients. Among them, 30 had received an  
159 empirical antibiotherapy prior to bacteriological sampling. In these 35 patients, the diagnosis



160 of graft infection was based on the presence of a periprosthetic abscess (n=13), a cutaneous  
161 fistula (n=9), a prosthetic-digestive fistula (n=5), a PA and an inflammatory syndrome (n=7), a  
162 periprosthetic urinoma and an inflammatory syndrome (n=1).

163

### 164 **Operative Data**

165 Per-operative data concerning the surgical technique is reported in [Table 3](#).

166 Regarding patients who underwent a 2-stage surgery: all cases of bleeding were treated with  
167 local repair (direct suture or a short graft interposition). In case of severe sepsis upon  
168 presentation, an abscess drainage was performed before graft explantation. In case of acute  
169 ischemia secondary to septic thrombosis, embolectomy was systematically performed.

170 A mean number of  $8.6 \pm 7$  blood units were transfused, corresponding to a mean blood loss of  
171  $3.7 \pm 3.7$  L per patient.

172 A mean number of 2 CAAs were used per patient. The cryopreserved arterial segments used  
173 were the descending thoracic aorta, the aortic bifurcation and one iliofemoral artery in 40.0,  
174 43.5 and 50.5% of patients, respectively. One or more calcifications were present in 44.7% of  
175 CAAs. The mean age of donors was  $39 \pm 13.3$  years. These factors were not predictive of  
176 long-term degeneration of the allograft.

177

### 178 **Postoperative Outcomes**

179 The 30-day mortality rate was 11% (n=22). The overall mortality rate was 14% (n=28) before  
180 discharge (the causes of death are listed in [table 4](#)). This rate was even much higher in  
181 patients with aorto-enteric fistulas (21%). Early reinfections (<1 month) were associated with  
182 a significantly higher rate of in-hospital mortality compared to late reinfections (>1 month),  
183 with mortality rates of 27.6% and 11.7%, respectively (OR=0.35 [0.13-1.04],  $p=.030$ ).

184 The in-hospital morbidity rate was 57.5% (the postoperative complications are listed in [Table](#)

185 4). In-hospital revision surgery was needed in 59 patients (29.5%) (detailed in Table 5) of  
186 whom 14 died. Among the 59 cases of revision surgery, 15 were related to the allograft (7.5%)  
187 and led to the death of 3 patients (Table 6).

188 The predictive factors for post-operative death identified in the multivariate analysis were: the  
189 age (OR = 2.9 [1.5-5.5] for 10 years,  $p=.001$ ), the presence of postoperative acute renal failure  
190 (OR = 3.8 [1.3-11.2],  $p=.014$ ) and the number of transfused blood units (OR = 4.2 [1.8-9.8],  
191  $p<.001$ ) (Table 7).

192 Among the 172 patients who survived during the early postoperative period, the mean follow-  
193 up was  $4.1\pm 3.9$  years (median = 2.9 years, IQR 4.8 years). Fifty-three patients (26.5%) were  
194 lost to follow-up, of whom 38 during the first 3 years. Fifteen were still alive at 3 years but  
195 were lost to follow-up thereafter.

196 The 1-, 3- and 5-year survival rates were respectively 76%, 66% and 56% (Figure 1).

197 During the follow-up, 59 other patients died after the early postoperative period. The most  
198 common causes were cancer (n=16), extravascular infectious disease (n=11), heart disease  
199 (n=6). Six allograft-related deaths due to a rupture were reported (Table 6).

200

#### 201 **Allograft-related events**

202 Seven late major amputations were reported during the follow-up, 2 were related to the  
203 allograft.

204 The 1-, 3- and 5-year primary patency rates were respectively 92%, 84% and 80% (Figure 1).

205 The 5-year limb salvage rate was 90% (Figure 1).

206 The rates of patients free from allograft-related revision surgery were 85%, 77% and 70% at 1,  
207 3 and 5 years, respectively (Figure 1) and the 30-day rate of allograft revision surgery was 6%.

208 The rate of allograft-related mortality was 3% (n=6 deaths).

209 All allograft-related complications are reported in Table 6.

210 Each allograft-related complication was reviewed: 27 patients required revision surgery  
211 during the first 6 months (Table 6). Seventeen patients experienced a complete or partial (PA)  
212 rupture of the allograft and 3 experienced an anastomotic tear or collateral bleeding. Among  
213 these 17 patients, 5 died (including 2 before revision surgery) and 4 experienced successive  
214 ruptures. The bacteriological samples collected during revision surgery were positive or  
215 multiple ruptures occurred in all cases except one. A total of 22 interventions were performed.  
216 Redo surgery consisted in a partial replacement with a new segment of allograft (n=13),  
217 saphenous vein (n=3), *in situ* rifampicin-bounded prosthesis (n=3), stent-graft (n=1),  
218 resection-anastomosis (n=1) and total resection + axillo-bifemoral prosthetic bypass (n=1).  
219 All *in situ* prostheses except one were secondarily infected and explantation was needed. The  
220 first revision surgery was performed after less than 6 weeks in 13 out of the 17 patients.

221 In the multivariate analysis, diabetes (HR = 4.18 [1.74-10.01],  $p = .001$ ) and pseudo-  
222 aneurysm upon presentation (HR = 2.92 [1.18-7.23],  $p = .020$ ) were the only predictive  
223 factors for allograft rupture before 6 months. The type of microorganisms and bowel fistulas  
224 were not associated with an increased risk of rupture (Supplementary Table 1).

225 After 6 months, 25 patients (18%, n=25/139) experienced an allograft-related complication  
226 (Table 6). Two ruptures were consecutive to two late allograft-related enteric fistulas (at 12  
227 and 20 months) responsible for 1 death. PA occurred later in 6 patients (1 at 7 months, 2 at 3  
228 years, 3 at 10 years). The PA that occurred at 7 months was a recurrence of a previous PA that  
229 occurred after less than 6 months.

230 The 1-, 3- and 5-year CAA reinfection rates were 10, 12 and 12%, respectively.

231

## 232 Discussion

233 This series of patients allowed quantifying the complication rate of surgery for abdominal  
234 aortic graft infection, in particular allograft-related complications from a homogenous cohort

235 of patients. Despite the acceptable results achieved with allografts used as a substitute for  
236 infected aortic prostheses, a significant rate of early failures was observed, leading to an  
237 increased risk of mortality.

238 The early mortality rate found in this study was acceptable (11%) compared to that reported  
239 by Antonopoulos<sup>12</sup> (14.9%) although the rate of enteric fistulas upon presentation was higher.  
240 Enteric fistulas were not associated with a significantly increased mortality rate contrary to  
241 what has been reported in other studies<sup>6,11,16,17</sup>, probably because of our aggressive  
242 intervention at the bowel defect that prevented fistula recurrence<sup>15</sup>.

243 The most common risk factors for early death from aortic sepsis treated with *in situ* allografts  
244 reported in the literature are the age of the patient<sup>6,7,18</sup>, the need for emergent surgery<sup>7,11,17</sup>,  
245 and enterobacteria and *Candida* infections<sup>3,19</sup>. However, the only significant independent  
246 predictors for death identified in our multivariate analysis were the age of the patient, the  
247 presence of post-operative acute renal failure, and the number of transfused blood units  
248 reflecting the invasiveness of such a surgery.

249 Our results confirmed that AGI remains a huge surgical challenge with a high morbidity rate  
250 (57%) falling within the range of values reported in Antonopoulos meta-analysis<sup>12</sup>. The septic  
251 and hemorrhagic context of AGI, the physiological consequences of the surgical procedure,  
252 and frequent age-related comorbidities could explain such a high complication rate. That is  
253 why a high-volume center with a specialized intensive care unit is crucial for the management  
254 of such patients.

255

### 256 **Short-term Allograft-Related Complications**

257 Our rate of allograft-related revision surgery during the first 6 post-operative months was 13.5%  
258 (n=27). Among these cases, 3 were due to collateral bleeding and 7 to early thrombosis or  
259 stenosis. However, the most worrisome causes of allograft-related revision surgery were

260 ruptures (n=17, 8.5%) since they were responsible for 5 deaths (2.5%).

261 Similarly, the resistance to infection and technical safety have been questioned due to a  
262 relatively high rate of early ruptures of 5.9% in a recent meta-analysis<sup>12</sup>. Subadventitial  
263 rupture can occur as a result of a default in the freezing/thawing process, leading to  
264 microcracks in CAA structure as shown in some historical reports when the process was still  
265 immature<sup>20,21</sup>.

266 However, after reviewing all cases of postoperative rupture or PA, we observed that among  
267 the 17 patients for whom redo surgery was needed, all except one had positive bacterial  
268 samples or multiple ruptures, supporting CAA infection rather than mechanical rupture  
269 induced by cryopreservation.

270 CAAs have shown their resistance to colonization by the microorganisms involved in AGI in  
271 *in vitro*<sup>22</sup>, *in vivo*<sup>8-10,23</sup> and clinical<sup>12</sup> studies. But CAA ruptures secondary to persistent  
272 infection are poorly defined in the literature.

273 We did not identify any pathogen that could be more prone to induce rupture, unlike some  
274 studies that have identified *P. aeruginosa* or *Candida spp* as necrotizing organisms<sup>13</sup>. But we  
275 showed that infections leading to PA of the native artery, regardless of the microorganism  
276 involved, appeared to be associated with a higher risk of early allograft rupture. The  
277 systematic collection of data on bacterial phenotypes involved in AGI is a promising field of  
278 investigation since some of them could be more likely to induce a disruption of the aortic wall,  
279 but unfortunately it was not included in our protocol. From this perspective, a proteomic  
280 analysis could be proposed in the future to compare bacterial strains responsible for rupture.

281 In addition, 8 other patients experienced a rupture or a PA of the CAA, but they occurred 3-10  
282 years after CAA implantation, supporting a degenerating process rather than the consequence  
283 of persistent infection. In summary, a recurrence of CAA rupture mainly occurred within six  
284 months of surgery and was related to infection recurrence and was found in about 8.5% of our

285 patients. Special care should be taken in case of PA upon presentation, for which a close  
286 imaging monitoring is needed during the first 6 months. A duplex ultrasound examination  
287 should be performed weekly for the first 6 weeks and then monthly thereafter to early detect a  
288 CAA rupture. In case of successive ruptures, allograft explantation combined with prosthetic  
289 extra-anatomic bypass should be considered.

290 The recommended duration of targeted postoperative antibiotherapy varies from 2 weeks to 6  
291 months or even lifelong<sup>13</sup>. However, most authors, including us, recommend a 6-week  
292 duration<sup>24</sup>, especially since most (13/17) CAA ruptures occurred during this period.

293 Harlander-Locke et al.<sup>3</sup> have found that the partial excision of the infected graft was a  
294 significant predictor for failure, confirming our doctrine consisting in systematically resecting  
295 all synthetic material and tissues, grossly infected or not, before allografting as  
296 recommended<sup>13</sup>.

297 Although the lack of bacteriological confirmation has not been associated with a pejorative  
298 predictive factor, effort should be made to avoid it, in order to provide appropriate  
299 antibiotherapy<sup>13</sup>. In this case, our institutional protocol recommends the use of antibiotics  
300 targeting Gram-negative bacillus for 5 days and Gram-positive cocci for 12 days after graft  
301 removal. This protocol is based on the bacteriological spectrum we identified.

302

### 303 **Mid-term Allograft-Related Complications**

304 Allografts are known to degenerate over time. In our experience as in that of others, late  
305 occlusive degeneration is nowadays much more frequent than aneurysmal degeneration (0-  
306 11.1% and 0-4.9%, respectively)<sup>3-5,7,12,25</sup>. Our conclusion was that the continuous  
307 improvement of the methods for obtaining and preserving CAAs will probably eradicate late  
308 aneurysmal degeneration. Even if an occlusive disease is easily treated using endovascular  
309 techniques<sup>7</sup>, such a high rate remains a concern. Because of the limited life expectancy of

310 patients and the small size of series, the rate of late occlusive degeneration remains imprecise.  
311 In our subgroup of patients still alive at five years, the rate of late occlusive degeneration  
312 requiring revision after 6 months was 18% and involved the iliofemoral segment of the CAA  
313 in 61.5% of cases. The etiology of late CAA degeneration remains controversial with several  
314 theories, including a chronic immune rejection as reported in the arteries of transplanted  
315 organs<sup>26</sup> or a lower resilience to mechanical stress than native tissues as suggested for the  
316 mechanisms of late calcification of valvular allografts<sup>27</sup>. Thus, CAA do not appear as an ideal  
317 arterial substitute if their late complications are taken into account.

318 Nevertheless, in the published studies with the longest follow-up, the 5-year survival rate  
319 ranges between 50% and 64%<sup>3,4,11,25,28</sup>. In our study, with a mean survival of 7.6 years, this  
320 rate was 57%. Thus, it could be assumed that the sustainability of CAAs is in line with such a  
321 survival. Cryopreservation definitely did not prevent the need for late revision surgery, with a  
322 rate of 25% at 5 years in our study and of 20% in the study by Harlander-Locke et al.<sup>3</sup> in 220  
323 patients. The quality of the CAA was also investigated: we concluded that the age of the  
324 donor, but also the presence of calcifications were not predictive factors for long-term  
325 complications. This result could support an extension of the criteria for artery harvesting in  
326 order to compensate the low availability of CAA. However, late revision surgery consists  
327 generally in limited “house-keeping” interventions associated with fairly low mortality and  
328 morbidity rates.

329 The limitations of our study include its retrospective design and the inherent inaccuracy that it  
330 implies, in particular with regard to antibiotic treatments: as a matter of fact, treatment  
331 duration and the precise time between the detection of a microorganism and the initiation of  
332 targeted antibiotics were poorly documented. Also, the lack of bacteriological confirmation in  
333 35 patients could have led to an analysis bias due to the inability to administer an adapted  
334 antibiotic. In addition, data from patients who were not candidates for surgery were not

335 collected in this study. But non-eligibility criteria were based on patient age and general  
336 condition regardless of the septic event, as for any standard aortic surgery. Moreover, the  
337 number of patients lost to follow-up could also have induced a bias for the long-term results  
338 of CAA.

339

## 340 **Conclusion**

341 CAAs provide acceptable results to treat aortic graft infection despite early graft-related  
342 reinfections. For that reason, it is recommended to bacteriologically confirm infection before  
343 initiating antibiotherapy and to perform a rigorous imaging follow-up. This study showed that  
344 this type of surgery is associated with a high morbidity due to patients' comorbidities and  
345 surgery invasiveness and a high-volume center is thus needed to performed it. Mid-term  
346 allograft-related complications were quite common but associated with low mortality and  
347 amputation rates.

348

349

350 **Conflict of Interest/Funding:** None

351

## 352 **References**

- 353 1. Berger P, Vaartjes I, Moll FL, De Borst GJ, Blankensteijn JD, Bots ML. Cumulative  
354 incidence of graft infection after primary prosthetic aortic reconstruction in the  
355 endovascular era. *Eur J Vasc Endovasc Surg.* 2015;49:581-585.
- 356 2. Vogel TR, Symons R, Flum DR. The incidence and factors associated with graft  
357 infection after aortic aneurysm repair. *J Vasc Surg.* 2008;47:264-269.
- 358 3. Harlander-Locke MP, Harmon LK, Lawrence PF, Oderich GS, McCreedy RA, Morasch  
359 MD, et al. The use of cryopreserved aortoiliac allograft for aortic reconstruction in  
360 the United States. *J Vasc Surg.* 2014;59:669-674.
- 361 4. Bisdas T, Bredt M, Pichlmaier M, Aper T, Wilhelmi M, Bisdas S, et al. Eight-year  
362 experience with cryopreserved arterial homografts for the in situ reconstruction of  
363 abdominal aortic infections. *J Vasc Surg.* 2010;52:323-330.



- 364 5. Brown KE, Heyer K, Rodriguez H, Eskandari MK, Pearce WH, Morasch MD. Arterial  
365 reconstruction with cryopreserved human allografts in the setting of infection: A  
366 single-center experience with midterm follow-up. *J Vasc Surg.* 2009;49:660-666.
- 367 6. Garot M, Delannoy PY, Meybeck A, Sarraz-Bournet B, d'Elia P, d'Escrivan T, et al.  
368 Intra-abdominal aortic graft infection: prognostic factors associated with in-hospital  
369 mortality. *BMC Infect Dis.* 2014;14:215.
- 370 7. Touma J, Cochennec F, Parisot J, Fialaire Legendre A, Becquemin JP, Desgranges P. In  
371 situ reconstruction in native and prosthetic aortic infections using cryopreserved  
372 arterial allografts. *Eur J Vasc Endovasc Surg.* 2014;48:292-299.
- 373 8. Knosalla C, Goeau-Brissonniere O, Leflon V, Bruneval P, Eugene M, Pechere JC, et al.  
374 Treatment of vascular graft infection by in situ replacement with cryopreserved  
375 aortic allografts: an experimental study. *J Vasc Surg.* 1998;27:689-698.
- 376 9. Koskas F, Goeau-Brissonniere O, Nicolas MH, Bacourt F, Kieffer E. Arteries from  
377 human beings are less infectible by *Staphylococcus aureus* than  
378 polytetrafluoroethylene in an aortic dog model. *J Vasc Surg.* 1996;23:472-476.
- 379 10. Litzler PY, Thomas P, Danielou E, Lucq J, Jacques B, Frebourg N, et al. Bacterial  
380 resistance of refrigerated and cryopreserved aortic allografts in an experimental  
381 virulent infection model. *J Vasc Surg.* 1999;29:1090-1096.
- 382 11. Kieffer E, Gomes D, Chiche L, Fleron MH, Koskas F, Bahnini A. Allograft replacement  
383 for infrarenal aortic graft infection: early and late results in 179 patients. *J Vasc Surg.*  
384 2004;39:1009-1017.
- 385 12. Antonopoulos CN, Papakonstantinou NA, Hardy D, Lyden SP. Editor's Choice -  
386 Cryopreserved Allografts for Arterial Reconstruction after Aorto-Iliac Infection: A  
387 Systematic Review and Meta-Analysis. *Eur J Vasc Endovasc Surg.* 2019;58:120-128.
- 388 13. Chakfe N, Diener H, Lejay A, Assadian O, Berard X, Caillon J, et al. Editor's Choice -  
389 European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the  
390 Management of Vascular Graft and Endograft Infections. *Eur J Vasc Endovasc Surg.*  
391 2020;59:339-384.
- 392 14. Teebken OE, Bisdas T, Assadian O, Ricco JB. Recommendations for reporting  
393 treatment of aortic graft infections. *Eur J Vasc Endovasc Surg.* 2012;43:174-181.
- 394 15. Schoell T, Manceau G, Chiche L, Gaudric J, Gibert H, Tresallet C, et al. Surgery for  
395 secondary aorto-enteric fistula or erosion (SAEFE) complicating aortic graft  
396 replacement: a retrospective analysis of 32 patients with particular focus on digestive  
397 management. *World J Surg.* 2015;39:283-291.
- 398 16. Gabriel M, Pukacki F, Dzieciuchowicz L, Oszkinis G, Checinski P. Cryopreserved arterial  
399 allografts in the treatment of prosthetic graft infections. *Eur J Vasc Endovasc Surg.*  
400 2004;27:590-596.
- 401 17. Verhelst R, Lacroix V, Vraux H, Lavigne JP, Vandamme H, Limet R, et al. Use of  
402 cryopreserved arterial homografts for management of infected prosthetic grafts: a  
403 multicentric study. *Ann Vasc Surg.* 2000;14:602-607.
- 404 18. Legout L, Sarraz-Bournet B, D'Elia PV, Devos P, Pasquet A, Caillaux M, et al.  
405 Characteristics and prognosis in patients with prosthetic vascular graft infection: a  
406 prospective observational cohort study. *Clin Microbiol Infect.* 2012;18:352-358.
- 407 19. Ali AT, Modrall JG, Hocking J, Valentine RJ, Spencer H, Eidt JF, et al. Long-term results  
408 of the treatment of aortic graft infection by in situ replacement with femoral  
409 popliteal vein grafts. *J Vasc Surg.* 2009;50:30-39.

- 410 20. Muller-Schweinitzer E. Cryopreservation of vascular tissues. *Organogenesis*.  
411 2009;5:97-104.
- 412 21. Pukacki F, Jankowski T, Gabriel M, Oszkinis G, Krasinski Z, Zapalski S. The mechanical  
413 properties of fresh and cryopreserved arterial homografts. *Eur J Vasc Endovasc Surg*.  
414 2000;20:21-24.
- 415 22. Camiade C, Goldschmidt P, Koskas F, Ricco JB, Jarraya M, Gerota J, et al. Optimization  
416 of the resistance of arterial allografts to infection: comparative study with synthetic  
417 prostheses. *Ann Vasc Surg*. 2001;15:186-196.
- 418 23. Moore WS, Swanson RJ, Campagna G, Bean B. The use of fresh tissue arterial  
419 substitutes in infected fields. *J Surg Res*. 1975;18:229-233.
- 420 24. Revest M, Camou F, Senneville E, Caillon J, Laurent F, Calvet B, et al. Medical  
421 treatment of prosthetic vascular graft infections: Review of the literature and  
422 proposals of a Working Group. *Int J Antimicrob Agents*. 2015;46:254-265.
- 423 25. Ben Ahmed S, Louvancourt A, Daniel G, Combe P, Duprey A, Albertini JN, et al.  
424 Cryopreserved arterial allografts for in situ reconstruction of abdominal aortic native  
425 or secondary graft infection. *J Vasc Surg*. 2018;67:468-477.
- 426 26. Merola J, Jane-Wit DD, Pober JS. Recent advances in allograft vasculopathy. *Curr Opin*  
427 *Organ Transplant*. 2017;22:1-7.
- 428 27. Schoen FJ, Levy RJ, Piehler HR. Pathological considerations in replacement cardiac  
429 valves. *Cardiovasc Pathol*. 1992;1:29-52.
- 430 28. Lejay A, Delay C, Girsowicz E, Chenesseau B, Bonnin E, Ghariani MZ, et al.  
431 Cryopreserved Cadaveric Arterial Allograft for Arterial Reconstruction in Patients with  
432 Prosthetic Infection. *Eur J Vasc Endovasc Surg*. 2017;54:636-644.  
433
- 434

## Figure Legends

435

436

437

438

439 Figure 1

440 Cumulative Kaplan-Meier estimates with 95% confidence intervals of (A) survival, (B)

441 primary patency, (C) freedom from allograft reintervention, (D) limb salvage after use of

442 cryopreserved abdominal aortic allografts as a substitute for infected prosthetic grafts in 200

443 patients.

444

445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453

Copy editors: please note that only the critical style editing has been made to these tables. Full copy editing is still needed. I have used green background color to highlight the edits that should be repeated in the following rows in the same column. After having moved the percentages from the last column to the previous column, please delete the last column. Please note that the hierarchy for the first column should be created by italics and indenting, not by bolding the texts.

## Tables

Variable	Patients (n=200)	
<b>Demographics</b>		
Age - years	64.2 ± 9.4	-
Male	184 (92)	
Female	16	(8)
<b>Cardiovascular risk factors</b>		
Hypertension	122	(61)
Diabetes	29	(14.5)
Dyslipidemia	98	(49)
Smoking	181	(90.5)
<b>Comorbidities</b>		
COPD	46	(23)
Chronic renal disease	33	(16.5)
Dialysis	5	(2.5)
Coronary artery disease	54	(27)
PAD	144	(72)
<b>ASA score</b>		
I	1	(0.5)
II	95	(47.5)
III	97	(48.5)
IV	7	(3.5)
<b>Indication for allograft</b>		
<i>Prostheto-digestive fistula</i>	56	(28)
<i>Periprosthetic abscess</i>	68	(34)
<i>Cutaneous fistula</i>	43	(21.5)
<i>Graft thrombosis + microbio (+)</i>	6	(3)
<i>PA + microbio (+)</i>	20	(10)
<i>PA + inflam syndrome</i>	7	(3.5)
<b>Initial bypass</b>		
Aorto-femoral	139	(69.5)
Aorto-iliac	30	(15)
Aorto-aortic	17	(8.5)
Ilio-femoral bypass	4	(2)
Axillo-bifemoral bypass	3	(1.5)
Cross-over femoro-femoral bypass	3	(1.5)
EVAR	2	(1)
Aorto-popliteal bypass	1	(0.5)
Aorto-aortic + Aorto-birenal bypass	1	(0.5)

454  
455  
456  
457  
458  
459  
460  
461  
462

**Table 1:** Preoperative characteristics of 200 patients with aortic graft infection.

Data are presented as *n* (%) or mean ± standard deviation. COPD = Chronic Obstructive Pulmonary Disease; PAD= Peripheral Arterial Disease, ASA= American Society of Anesthesiologists; PA=Pseudo-aneurysm VGI = Vascular Graft Infection; EVAR = endovascular aneurysm repair.

Microorganism	Patients (n = 200)	
<i>Staphylococcus Aureus</i>	62 (31.6) †	
<i>Escherichia Coli</i>	42 (21.4)	
Coagulase-negative <i>Staphylococcus</i>	32	(16.3)
<i>Enterococcus</i>	29	(14.8)
<i>Pseudomonas Aeruginosa</i>	28	(14.3)
<i>Candida sp.</i>	24	(12.2)
<i>Streptococcus</i>	25	(12.8)
<b>Other enterobacteria</b>	19	(9.7)
<b>Anaerobes</b>	12	(6.1)
<i>Proteus sp.</i>	11	(5.6)
<i>Klebsiella sp.</i>	10	(5.1)
<i>Citrobacter</i>	4	(2)
Other yeasts	2	(1)
<b>Number of microorganisms per patient*</b>		
None	35	(17.9)
1	74	(37.8)
2	35	(17.9)
3 or more	52	(26.4)

464

465 **Table 2:** Microorganisms responsible for infection, identified in local samples (periprosthetic  
466 abscess or graft) or blood cultures in 200 patients with aortic graft infection.

467

468

469

470 Data are presented as *n* (%). Sp. = Species.

471 \*4 with missing data

472 † 23 Methicillin-resistant *Staphylococcus Aureus*

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489  
490  
491  
492  
493

	Patients (n = 200)	
<b>One-step emergent surgery</b>	<b>15 (7.5)</b>	
<b>Two-step emergent surgery</b>	<b>68</b>	<b>(34)</b>
Hemostasis first	33	(16.5)
Abscess drainage first	30	(15)
Revascularization first (for acute ischemia)	5	(2.5)
<b>Separation of the allograft from the bowels</b>	<b>200</b>	<b>(100)</b>
Retroperitoneal tissue	126	(63)
Omentoplasty	69	(34.5)
Pericardial patch	5	(2.5)
<b>Sartorius plasty</b>	<b>26</b>	<b>(13)</b>
<b>Duodenum fistula repair</b>	<b>36</b>	<b>(18)</b>
Direct suture	22	(11)
Resection/anastomosis	14	(7)
<b>Small bowel fistula repair</b>	<b>12</b>	<b>(6)</b>
Direct suture	6	(3)
Resection/anastomosis	6	(3)
<b>Colonic fistula repair</b>	<b>8</b>	<b>(4)</b>
Direct suture	1	(0.5)
Resection	7	(3.5)

494  
495  
496  
497  
498  
499  
500

**Table 3:** Peroperative features according to the surgical technique in 200 patients with aortic graft infection.

Data are presented as *n* (%).

501

	Morbidity - n		Deaths - n
<b>Cardiac</b>	<b>36 (18)</b>		
Myocardial infarction	17	(8.5)	1
Cardiac arrhythmia	10	(5)	0
Acute pulmonary edema	4	(2)	0
Cardiac arrest	3	(1.5)	0
Cardiogenic shock	2	(1)	1
<b>Pulmonary</b>	<b>45</b>	<b>(22.5)</b>	
Pneumopathy	34	(17)	2
Atelectasis	10	(5)	0
ARDS	1	(0.5)	1
Pulmonary embolism	1	(0.5)	1
<b>Digestive</b>	<b>30</b>	<b>(15)</b>	
Ischemic colitis	14	(7)	3
Digestive bleeding	5	(2.5)	0
Bowel occlusion	4	(2)	0
Pancreatitis	4	(2)	0
Cholecystitis	3	(1.5)	0
<b>Renal</b>	<b>63</b>	<b>(31.5)</b>	
Acute renal failure	49	(24.5)	0
Acute renal failure with dialysis	14	(7)	0
<b>Septic shock</b>	<b>21</b>	<b>(10.5)</b>	<b>8</b>
<b>Hemorrhagic shock</b>	<b>10</b>	<b>(5)</b>	<b>6</b>
<b>Multiorgan failure</b>	<b>5</b>	<b>(2.5)</b>	<b>5</b>

502

503

**Table 4:** Morbidity and causes of death during the postoperative in hospital period in 200 patients with aortic graft infection.

504

505

506

507

Data are presented as n (%). ARDS: Acute Respiratory Distress Syndrome.

508

509

510

511

512

513

514

515

516

517



518  
519  
520  
521  
522  
523

Complications requiring revision surgery	Patients (n = 200)	
<b>Related to the allograft</b>	<b>15 (7.5)</b>	
Rupture	6	(3)
Pseudoaneurysm	2	(1)
Tear or collateral bleeding	3	(1.5)
Thrombectomy	2	(1)
Stenosis	2	(1)
<b>Not related to the allograft</b>	<b>46</b>	<b>(23)</b>
Major amputation	9	(4.5)
Minor amputation	2	(1)
Lower limb revascularization	8	(4)
Wound infection drainage	5	(2.5)
Deep abscess drainage	6	(3)
Hemostasis	5	(2.5)
Colectomy (ischemic colitis)	12	(6)
Cholecystectomy	3	(1.5)
Bowel occlusion	2	(1)
Nephrostomy	2	(1)
Enteric fistula repair	1	(0.5)
Jejunostomy closure	1	(0.5)
Evisceration	1	(0.5)

524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539

**Table 5:** Inpatient complications requiring revision surgery during the postoperative hospital stay after allograft implantation for aortic graft infection in 200 patients. A given patient could experience several complications.

Data are presented as *n* (%).

540  
541  
542  
543

Complication	<6 months (n = 200)				>6 months (n = 139)	
	In-hospital		0-6 months		Patients	Deaths
	Patients	Deaths	Patients	Deaths		
Rupture	6 (3)	3 (1.5)	10 (5)	5 (2.5)	2 (1.4)	1 (0.7)
Pseudoaneurysm	2 (1)	0	7 (3.5)	0	6 (4.3)	0
Tear or collateral bleeding	3 (1.5)	0	3 (1.5)	0	0 (0)	0
Thrombosis	2 (1)	0	5 (2.5)	0	11 (8)	0
Stenosis	2 (1)	0	2 (1)	0	4 (2.9)	0
Aneurysm	0 (0)	0	0 (0)	0	2 (1.4)	0

544  
545  
546  
547  
548  
549

**Table 6:** Allograft-related complications and mortality during follow-up in 200 patients with aortic graft infection.

Data are presented as *n* (%).

Parameters	Univariate analysis		Multivariate analysis	
	OR (95% CI)	p value	OR (95% CI)	p value
No bacteria in samples	*	.006		
Pseudomonas Aeruginosa	2.02 (0.73-5.58)	.22		
MRSA	2.01 (0.68-5.98)	.20		
Candida	3.32 (1.22-9.02)	.023		
Anaerobia	1.33 (0.28-6.46)	.66		
Enterobacteria	2.33 (1.01-5.38)	.043		
Age	2.58 (1.15-5.82)	.019	2.90 (1.53-5.50)	.001
ASA score	0.03 (0.42-2.07)	.86		
Preoperative antibiotics	0.72 (0.23-2.23)	.56		
Antibiotics		.95		
- Non selective vs selective	1.19 (0.45-3.13)			
- No antibiotics vs selective	0.82 (0.27-2.45)			
Hypertension	0.85 (0.37-1.95)	.70		
Diabetes	0.67 (0.19-2.39)	.78		
CKD	1.46 (0.54-3.95)	.42		
COPD	1.14 (0.45-2.87)	.78		
Coronaropathy	0.70 (0.27-1.84)	.47		
Emergency surgery	5.4 (1.86-15.7)	.004		
Digestive fistula	2.12 (0.93-4.81)	.070		
Preoperative hemorrhagy	1.43 (0.44-4.57)	.52		
Clamping level		<.001		
- Infra renal	1			
- Inter renal	0.59 (0.16-2.23)			
- Supra renal	5.10 (1.98-13.10)			
- Coeliac	2.23 (0.42-11.83)			
Intraoperative shock	6.05 (2.5-14.64)	<.001		
Postoperative ARF	3.87 (1.67-8.94)	<.001	3.84 (1.32-11.20)	.014
Postoperative dialysis	4.12 (1.26-13.4)	.027		
Amputation	1.81 (0.36-9.21)	.62		
Major medical complication	4.56 (1.64-12.7)	<.001		
Preoperative septic shock	4.33 (0.69-27.18)	.14		
Hypogastric reimplantation	2.17 (0.55-8.58)	.38		
Number of transfused blood units	4.4 (2.2-8.7)	<.001	4.23 (1.83-9.78)	<.001
Early revision surgery	3.43 (1.41-8.30)	.011		

550  
551  
552  
553

**Table 7.** Uni- and multivariate analysis of early mortality in 200 patients treated with cryopreserved abdominal aortic allograft for aortic graft infection.

554

555

556 *MRSA : Methicillin-Resistant Staphylococcus Aureus ; ASA : American Society of*  
557 *Anaesthesiologists ; CKD : Chronic Kidney Disease ; COPD : Chronic Obstructive Pulmonary*  
558 *Disease ; ARF : Acute Renal Failure .*

559

560 *\*: OR cannot be calculated in the absence of event*

561

562

563

